
Please try another search
(Reuters) -Regeneron Pharmaceuticals Inc reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea.
Eylea, which recorded total sales of $9.65 billion in 2022, has been a key growth driver for the company ever since its launch more than a decade ago. But analysts have flagged competition from Roche's Vabysmo, which was approved last year.
Sales of Eylea, used to treat vision loss causing age-related macular degeneration, were impacted by temporary closing of a fund during the quarter that provides co-pay assistance to patients. U.S. sales of the drug were down 3.3% to $1.50 billion in the fourth quarter.
However, the company last month said that patients, who had switched to a less expensive alternative, were already beginning to use Eylea again.
Quarterly sales of the company's Dupixent, recorded by its partner Sanofi (NASDAQ:SNY), rose 38% to $2.45 billion, with Regeneron (NASDAQ:REGN)'s collaboration revenue from the French company jumping about 61% to $836 million.
Dupixent is an anti-inflammatory drug, which was approved in 2017, and has also been a booster for Regeneron with the treatment currently approved for five indications, including asthma and atopic dermatitis, or eczema.
Excluding items, the company reported a profit of $12.56 per share for the quarter ended Dec. 31, above analysts' estimates of $10.03, according to Refinitiv IBES data.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.